Alginic Acid Market By Grade (Pharmaceutical Grade, Food Grade, Industrial Grade); By Application (Pharmaceutical Excipients, Gastrointestinal & Antacid Formulations, Food & Beverage Formulations, Industrial Processing, Other Specialty Applications); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Global Alginic Acid Market to Reach USD 74.9 Million by 2032 – (Updated On: 16th-Oct-2026)

The Global Alginic Acid Market was valued at USD 52.5 million in 2025 and is projected to reach USD 74.9 million by 2032, growing at a CAGR of 5.2% during 2026–2032, according to Strategic Market Research. Global consumption was estimated at approximately 4,200 metric tonnes. Pharmaceutical-grade alginic acid dominated with USD 30.6 million in revenue, representing 58.3% of the market, followed by food grade at USD 14.0 million and industrial grade at USD 7.9 million. Pharmaceutical excipients were the largest application at USD 20.1 million, while food and beverage formulations generated USD 14.2 million and gastrointestinal and antacid formulations contributed USD 8.4 million.

 

Asia-Pacific accounted for USD 22.6 million in 2025, representing 43.0% of global revenue. China was the largest national market at USD 10.5 million, followed closely by the United States at USD 10.0 million, while Japan contributed USD 4.1 million. The market has a specialized manufacturing base led by companies including KIMICA Corporation, JRS Pharma and Shandong Jiejing Group, particularly across pharmaceutical and food-grade products.

 

China Leads the Global Alginic Acid Market

China's Alginic Acid Market generated approximately USD 10.5 million in 2025, accounting for 20.0% of global revenue, and is projected to reach USD 16.2 million by 2032 at a CAGR of 6.4%. Pharmaceutical-grade material accounted for approximately 54% of national revenue, while pharmaceutical excipients represented 36% by application. China's position combines a sizeable pharmaceutical ingredient market with domestic alginic acid production.

Shandong Jiejing Group is among the country's established manufacturers of alginic acid and other seaweed-derived ingredients, supplying pharmaceutical and specialty applications. China's projected growth rate exceeds the global CAGR of 5.2%, with pharmaceutical-grade material remaining the country's largest revenue category through 2032.

 

United States Accounts for 19.0% of Global Revenue

The United States Alginic Acid Market was valued at approximately USD 10.0 million in 2025, representing 19.0% of global revenue, and is projected to reach USD 14.1 million by 2032 at a CAGR of 5.0%. Pharmaceutical-grade alginic acid accounted for approximately 65% of national revenue, while pharmaceutical excipients represented 43% by application, making regulated pharmaceutical formulations the country's principal market.

The United States Pharmacopeia–National Formulary maintains an Alginic Acid monograph, providing an established quality reference for pharmaceutical material. Food applications have separate regulatory recognition under U.S. FDA 21 CFR 184.1011, which permits alginic acid in specified food products subject to applicable conditions. These standards provide established specifications for suppliers serving pharmaceutical and food manufacturers in the United States.

 

Japan Maintains an Established Specialty Ingredient Market

Japan's Alginic Acid Market was valued at approximately USD 4.1 million in 2025 and is projected to reach USD 5.9 million by 2032, growing at a CAGR of 5.3%. Pharmaceutical-grade products represented approximately 66% of national revenue, giving Japan one of the highest pharmaceutical-grade shares among the major country markets.

Japan is also home to KIMICA Corporation, an established manufacturer of alginic acid and other alginate ingredients. KIMICA supplies products meeting FCC, NF and EP/BP specifications and reports more than 80% domestic market share across its broader alginate business. Its manufacturing and international distribution operations give Japan a significant position in specialty alginate supply beyond the size of its domestic alginic acid market.

 

Key Report Takeaways

By Grade

• Largest and Fastest-Growing – Pharmaceutical Grade: Accounted for 58.3% of global revenue (USD 30.6 million) in 2025, with a projected 5.8% CAGR during 2026–2032, supported by alginic acid's established use in tablet disintegration and pharmaceutical excipient formulations.

 

By Application

• Largest – Pharmaceutical Excipients: Represented 38.3% of global revenue (USD 20.1 million) in 2025, with an estimated 5.8% CAGR, reflecting alginic acid's use as a tablet disintegrant and binder in oral pharmaceutical formulations.

• Fastest-Growing – Gastrointestinal & Antacid Formulations: Accounted for 16.0% of market revenue (USD 8.4 million) in 2025, with a projected 6.6% CAGR, supported by specialized gastrointestinal medicines incorporating alginic acid and continued development of reflux treatment formulations.

 

By Geography

• Largest and Fastest-Growing – Asia-Pacific: Held 43.0% of global revenue (USD 22.6 million) in 2025, with an estimated 5.9% CAGR, supported by established alginic acid manufacturing in China and Japan and pharmaceutical ingredient requirements across major Asian economies.

 

Pharmaceutical Grade Dominates Alginic Acid Revenue

Pharmaceutical-grade alginic acid generated USD 30.6 million in 2025, representing 58.3% of global market revenue and approximately 1,800 metric tonnes of consumption. The segment is projected to reach USD 45.3 million by 2032 at a CAGR of 5.8%. Pharmaceutical excipients account for the largest share, particularly across oral solid dosage formulations.

Food-grade alginic acid accounted for USD 14.0 million, or 26.7% of global revenue, with approximately 1,400 metric tonnes consumed in 2025. Revenue is projected to reach USD 19.2 million by 2032 at a CAGR of 4.6%. Industrial-grade material represented the remaining 15.0%, equivalent to USD 7.9 million and approximately 1,000 metric tonnes, with revenue forecast to reach USD 10.4 million by 2032.

The revenue difference between pharmaceutical and other grades reflects the market's concentration in regulated applications. USP–NF and European Pharmacopoeia specifications provide established references for pharmaceutical material, while food-grade alginic acid is separately governed by applicable food ingredient standards.

 

Pharmaceutical Excipients Represent the Largest Application

Pharmaceutical excipients accounted for USD 20.1 million in 2025, representing 38.3% of global Alginic Acid Market revenue, and are projected to reach USD 29.9 million by 2032. Alginic acid has an established position in oral pharmaceutical formulations, including tablet applications. JRS Pharma supplies pharmaceutical alginic acid through its VIVAPHARM portfolio, with production at Landerneau Marine Technologies in Brittany, France.

Gastrointestinal and antacid formulations generated approximately USD 8.4 million in 2025, representing 16.0% of global revenue, and are projected to register a CAGR of 6.6% through 2032. This is the fastest growth rate among the major application categories. The segment specifically covers formulations containing alginic acid; products using sodium alginate or other alginate derivatives without alginic acid are excluded from the market assessment.

Food and beverage formulations accounted for approximately USD 14.2 million in 2025, equivalent to 27.0% of global revenue. Alginic acid is recognized as E400 in Europe and is permitted for specified food applications in the United States. Food applications therefore represent the second-largest market after pharmaceutical excipients, while industrial processing contributed USD 5.6 million and specialty applications accounted for approximately USD 4.2 million.

 

Asia-Pacific Holds 43.0% of Global Revenue

Asia-Pacific generated approximately USD 22.6 million in Alginic Acid Market revenue in 2025, representing 43.0% of the global market, and is projected to reach USD 33.8 million by 2032 at a CAGR of approximately 5.9%. China led the region at USD 10.5 million, followed by Japan at USD 4.1 million. India's market was estimated at USD 2.5 million, with pharmaceutical ingredient manufacturing representing an important application.

The region also contains two important manufacturing bases. Shandong Jiejing Group participates in China's seaweed-derived ingredient industry, while KIMICA Corporation maintains established production capabilities in Japan. China provides the region's largest domestic revenue contribution, while Japan has a stronger position in specialized pharmaceutical and food-grade alginate manufacturing.

 

Europe Represents 25.0% of the Global Market

Europe accounted for approximately USD 13.1 million in 2025, representing 25.0% of global Alginic Acid Market revenue, with sales projected to reach USD 18.0 million by 2032. Germany was the largest European national market at approximately USD 3.5 million, with pharmaceutical-grade material accounting for about 62% of national revenue. Germany is projected to reach USD 4.9 million by 2032.

France generated approximately USD 2.4 million in 2025 and has an established alginic acid manufacturing presence through Landerneau Marine Technologies in Brittany, which produces JRS Pharma's VIVAPHARM alginate products. JRS Pharma reports that brown algae used at the facility are sourced locally under regulated harvesting arrangements. KIMICA also maintains a European commercial presence in Düsseldorf, Germany.

Spain's market was estimated at approximately USD 1.0 million, with food-grade material accounting for roughly one-third of national revenue. Europe consequently combines pharmaceutical-focused markets such as Germany with food-oriented applications in Southern European countries and established ingredient production in France.

 

North America Accounts for 23.0% of Global Revenue

North America generated approximately USD 12.1 million in 2025, equivalent to 23.0% of global revenue, and is projected to reach USD 17.0 million by 2032. The United States accounted for approximately 82.8% of regional sales at USD 10.0 million, while Canada contributed USD 1.4 million and Mexico approximately USD 0.7 million.

Pharmaceutical-grade material represents the largest regional category, particularly in the United States. USP–NF recognition provides an established pharmaceutical quality reference, while FDA regulations define permitted food applications. North American revenue is therefore concentrated in pharmaceutical formulations and selected regulated food products rather than industrial-grade material.

Latin America accounted for approximately USD 2.6 million, or 5.0% of global revenue, with Brazil representing USD 1.4 million. Chile's domestic market was considerably smaller at approximately USD 0.3 million, although the country has greater importance in international alginate production through KIMICA's Alginatos Chile operations. The Middle East and Africa accounted for approximately USD 2.1 million, representing the remaining 4.0% of global revenue.

 

KIMICA, JRS Pharma and Shandong Jiejing Group Are Key Manufacturers

The Alginic Acid Market has a relatively specialized supplier base. KIMICA Corporation, JRS Pharma and Shandong Jiejing Group are among the established manufacturers identified across pharmaceutical, food and specialty alginic acid applications.

KIMICA Corporation supplies alginic acid through its KIMICA ACID portfolio and maintains manufacturing operations in Japan and Chile. Its product range includes grades meeting FCC, NF and European and British Pharmacopoeia specifications. The company's international presence includes commercial operations in Europe and other major ingredient markets.

JRS Pharma has an established pharmaceutical position through its VIVAPHARM Alginates portfolio. Its alginic acid is supplied for oral pharmaceutical formulations and manufactured by Landerneau Marine Technologies in Brittany. The company reports regulated sourcing of brown algae and reuse or recycling of production by-products at the facility.

Shandong Jiejing Group represents an important Chinese production base for alginic acid and related marine ingredients. Its position is particularly relevant in China, which accounted for 20.0% of global revenue and is projected to grow at 6.4% annually through 2032.

Regulatory qualification is particularly important in pharmaceutical and food-grade competition. USP–NF, European Pharmacopoeia and applicable food standards establish specifications that distinguish regulated grades from general industrial material.

 

Recent Developments in Specialty Alginic Acid

In July 2026, Mochida Pharmaceutical published U.S. patent application US20260193427A1 for novel crosslinked alginic acid, covering modified materials with potential biomedical applications. The filing followed the company's receipt of U.S. Patent No. 12,617,905 in May 2026 for crosslinked alginic acid technology and related derivatives.

The patents indicate continuing development of specialized alginic acid materials for pharmaceutical and biomedical applications. These technologies represent specialty development activity and are separate from the conventional pharmaceutical, food and industrial alginic acid revenues included in the current market estimate. (Source: Google Patents – US20260193427A1)

 

Alginic Acid Market Research Methodology

Strategic Market Research assesses the Alginic Acid Market across pharmaceutical, food-grade and industrial applications using estimated consumption volumes, grade-specific pricing, country-level demand and manufacturer information. The market definition covers standalone alginic acid and excludes revenue attributable solely to sodium alginate, calcium alginate and other alginate derivatives, avoiding overlap with the wider alginate industry.

The 2025 assessment incorporates approximately 4,200 metric tonnes of global consumption across pharmaceutical excipients, gastrointestinal formulations, food and beverage applications, industrial processing and specialty uses. Grade, application and geographic revenues are reconciled with the global USD 52.5 million market estimate.

Supporting evidence includes the United States Pharmacopeia, U.S. FDA food regulations, European pharmaceutical standards and published information from KIMICA Corporation and JRS Pharma. These sources establish regulatory recognition, product availability and manufacturer participation, while market sizes, segment shares and forecasts remain Strategic Market Research estimates.

The Global Alginic Acid Market is projected to increase from USD 52.5 million in 2025 to USD 74.9 million by 2032 at a CAGR of 5.2%. Pharmaceutical grade remains the largest product category at 58.3% of revenue, pharmaceutical excipients lead applications at 38.3%, and Asia-Pacific holds the largest regional share at 43.0%.

 

Alginic Acid Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 52.5 Million
Revenue Forecast in 2032	USD 74.9 Million
Overall Growth Rate	5.2% CAGR
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Million, Metric Tonnes, CAGR (2026–2032)
Segmentation	By Grade; By Application; By Geography
By Grade	Pharmaceutical Grade, Food Grade, Industrial Grade
By Application	Pharmaceutical Excipients, Gastrointestinal & Antacid Formulations, Food & Beverage Formulations, Industrial Processing, Other Specialty Applications
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	China, United States, Japan, India, Germany, France, Spain, Canada, Mexico, Brazil, Chile
Market Drivers	The patents indicate continuing development of specialized alginic acid materials for pharmaceutical and biomedical applications.
Customization Option	Available upon request